- Home
- SKYE vs ESLA Comparison
SKYE vs ESLA Comparison
Compare SKYE & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYE | ESLA |
|---|---|---|
| Founded | 2012 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 48.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SKYE | ESLA |
|---|---|---|
| Price | $1.01 | $1.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $14.75 | $8.00 |
| AVG Volume (30 Days) | ★ 431.9K | 81.5K |
| Earning Date | 03-19-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $0.73 |
| 52 Week High | $5.75 | $3.15 |
Technical Indicators
Market Signals| Indicator | SKYE | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 50.53 | 39.14 |
| Support Level | $0.95 | $0.90 |
| Resistance Level | $1.07 | $1.13 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 45.80 | 22.79 |
Price Performance
Historical ComparisonAbout SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.